DBV TECHNOLOGIES SA (DBV.PA) 2.5 +0.05 (+2.12%)
2.5 +0.05 (+2.12%)
FR0010417345 - Common Stock
Fundamental Rating
We assign a fundamental rating of 2 out of 10 to DBV. DBV was compared to 49 industry peers in the Biotechnology industry. Both the profitability and financial health of DBV have multiple concerns. DBV has a expensive valuation and it also scores bad on growth
Profitability
Profitability Rating
The profitability ratios for DBV are negative, so there is not much use analyzing them.
DBV has a Return On Assets of -142.57%. This is below the industry average of -35.55%. 94% of the industry peers outperform DBV.
DBV has a Profit Margin of -1519.59%. This is below the industry average of -286.43%.
DBV has a very weak Piotroski-F score of 1.00. This is an indication of health and profitability issues for DBV.
VS Industry
ROA (-142.57%) VS Industry: 6% outperformed.
-154.47
65.73
Profit Margin (-1519.59%) VS Industry: 25% outperformed.
-470,040.00
326,680.00
Valuation
Valuation Rating
When comparing the price book ratio of DBV to the average industry price book ratio of 2.44, DBV is valued rather cheaply.
With a price book ratio of 1.29, DBV is valued correctly.
DBV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DBV. No positive earnings are expected for the next year.
VS Industry
Price/Book (1.29) VS Industry: 66% outperformed.
13.43
0.01
Growth
Growth Rating
DBV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 39.32%, which is quite impressive.
Based on estimates for the next 5 years, DBV will show a small growth in Earnings Per Share. The EPS will grow by 2.93% on average per year.
Looking at the last year, DBV shows a very negative growth in Revenue. The Revenue has decreased by -49.38% in the last year.
DBV shows a very negative growth in Revenue. Measured over the last 5 years, the Revenue has been decreasing by -10.44% yearly.
Based on estimates for the next 5 years, DBV will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | 39.32% | 2.08% | 2.94% | -11.33% | 2.93% |
| Revenue | -10.44% | -28.85% | -49.38% | -31.37% | -1.48% | -25.99% | -14.87% |
Health
Health Rating
DBV has a Current Ratio of 3.26. This indicates that DBV is financially healthy and has no problem in meeting its short term obligations.
DBV has a Quick Ratio of 3.26. This indicates that DBV is financially healthy and has no problem in meeting its short term obligations.
With a Debt to Equity ratio of 0.00, DBV is doing better than the averages in the industry. The industry average is at 0.05.
DBV has a Current Ratio comparable to the industry average, which is at 2.64.
The Quick Ratio is in line with the industry averages, which is at 2.64.
Based on the Altman-Z score of -4.22, we must say that DBV is in the distress zone and has some risk of bankruptcy.
Compared to an average industry Altman-Z score of 0.11, DBV is in worse financial health than its industry peers.
DBV has a very weak Piotroski-F score of 1.00. This is an indication of health and profitability issues for DBV.
VS Industry
Debt/Equity (0) VS Industry: 80% outperformed.
1.52
-7.86
Quick Ratio (3.26) VS Industry: 58% outperformed.
0.28
19.61
Current Ratio (3.26) VS Industry: 58% outperformed.
0.28
19.61
Altman-Z (-4.22) VS Industry: 24% outperformed.
-27.85
31.85
Dividend
Dividend Rating
No dividends for DBV!.
DBV TECHNOLOGIES SA2.5
EPA:DBV (5/17/2022, 7:00:00 PM)+0.05 (+2.12%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Biotechnology | ||
| Earnings (Last) | N/A N/A | Earnings (Next) | N/A N/A |
| Ins Owners | N/A | Inst Owners | N/A |
| Market Cap | 274.76M | Analysts | 70 |
| PE | N/A | Fwd PE | N/A |
| PEG (NY) | N/A | PEG (5Y) | N/A |
| P/S | 28.61 | P/B | 1.29 |
| EV/EBITDA | -1.93 | ||
| ROA | -142.57% | ROE | N/A |
| PM | -1519.59 | Asset Turnover | 0.08 |
| EPS 1Y | 39.32% | EPS 3Y | N/A |
| EPS 5Y | N/A | EPS growth Q2Q | 46.28% |
| EPS Next Y | 2.08% | EPS Next 2Y | 2.94% |
| EPS Next 3Y | -11.33% | EPS Next 5Y | 2.93% |
| Revenue growth 1Y | -49.38% | Revenue growth 3Y | -28.85% |
| Revenue growth 5Y | -10.44% | Revenue growth Q2Q | 44.43% |
| Revenue Next Year | -31.37% | Revenue Next 2Y | -1.48% |
| Revenue Next 3Y | -25.99% | Revenue Next 5Y | -14.87% |
| Current Ratio | 3.26 | Quick Ratio | 3.26 |
| Altman-Z | -4.22 | F-Score | 1 |
| Debt/Equity | N/A | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | N/A | Ex-Date | N/A |
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the EuroNext
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the EuroNext
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the EuroNext
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the EuroNext